<DOC>
	<DOCNO>NCT00454909</DOCNO>
	<brief_summary>The purpose study characterize safety immunogenicity 1 dose GSK Biologicals ' meningococcal vaccine GSK134612 compare Menactra® adolescents/adults 11-25 year age . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 . The protocol post update follow protocol amendment .</brief_summary>
	<brief_title>Immunogenicity Safety Meningococcal Vaccine GSK134612 vs. Menactra® Healthy Adolescent/Adults Aged 10-25 Years .</brief_title>
	<detailed_description>Subjects 11-25 year age randomize receive either meningococcal vaccine GSK134612 Menactra® . An additional non-randomized group subject age 10 year ( &lt; 11 year age ) enrol receive meningococcal vaccine GSK134612 ( At time study begin , Menactra® license United States individual 11 year age therefore could use control vaccine subject le 11 year old ) . This study single-blind subject 11 25 year age open subject 10 &lt; 11 year age .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female , include , 10 25 year age ( attain his/her 26th birthday ) time vaccination . Written inform consent obtain parents/guardian subject write informed assent obtain subject subject le 18 year age , write informed consent obtain subject subject achieve 18th birthday . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential , childbearing potential , must practice adequate contraception ( include abstinence ) 30 day prior vaccination , negative pregnancy test continue precaution 2 month vaccination . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccine dose . Planned administration/ administration vaccine foreseen study protocol within one month dose vaccine ( ) . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroup A , C W135 , and/or Y . Previous vaccination tetanus diphtheria toxoid within last month ( i.e. , Tdap , Td , TTcontaining vaccine within last month ) . History meningococcal disease due serogroup A , C , W135 , Y . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination ( laboratory testing require ) . A family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . History allergic disease reaction likely exacerbate component vaccine . Hypersensitivity latex . Major congenital defect serious chronic illness . History neurologic disorder seizure . Previous history GuillainBarré Syndrome . Bleeding disorder , hemophilia thrombocytopenia , subject anticoagulant therapy . Acute disease time enrollment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Meningococcal Serogroups A , C , W-135 and/or Y Disease</keyword>
</DOC>